Are Cell and Gene Therapy Innovations Ready for Widespread Use?

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

Treatment of diseases like cancer and HIV is hitting a new frontier with cell-based therapy. This new therapy invigorates the medical world, but it’s not widely accessible yet. Discussing the breakthroughs in these treatments, I Don’t Care host Kevin Stevenson spoke with immunologist Dr. Chris Xu, CEO of ThermoGenesis, a medical device company that’s a pioneer in the field.

“Cell-based therapy came about 13 years ago, and we’ve been fostering the field around cord blood, with 90% of FDA approved cord blood stored in a nitrogen system we developed,” Dr. Xu explained.

That was the company’s beginning, but it has aspirations to do much more. That requires a shift in treatment perspective. “We’ve long used drugs to treat illnesses, but cancer is much more complex. The newly approved therapy takes a patient’s T-cells, which are part of the immune system. It reprograms them to recognize cancer and fight it. It’s the future of medicine,” Dr. Xu said.

“Using someone’s T-cells turns their body into the best defense mechanism against disease.” – Dr. Chris Xu

Thus far, Dr. Xu reported that patients with leukemia and lymphomas have a 93% response rate. He also noted that cancer treatment is just the beginning. Over 1200 trials targeting every type of cancer are ongoing.

HIV is another disease where cell gene therapy has promise. “We discovered that a small percentage of the population doesn’t carry the receptor for HIV, which is necessary for the virus to enter a cell. We can modify cells not to have it, making the patient HIV resistant.”

While the promise of new treatments is here, Dr. Xu noted there are two big impediments. One is cost, with treatments costing as much as $500,000. The other is that patients may no longer have T-cells due to radiation, chemo, or other issues. That’s why he recommends storing cord blood for future use.

Listen to Previous Episodes of I Don’t Care!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

How Branded Moving Trucks Help Storage Facilities Attract More Customers
August 1, 2025

You know that feeling when you see the same truck three times in a week? First at the grocery store, then outside your friend’s place, then stuck in traffic next to you. By the third sighting, that company name is burned into your brain. Smart storage facility owners figured this out years ago. They’re…

Read More
Winter is Coming: 9 Battle-Tested Strategies to Shield Your Commercial Property from Skyrocketing Insurance Costs
August 1, 2025

The numbers are brutal. Insurance deductibles that used to be a manageable $2,000 flat fee have morphed into percentage-based nightmares tied to property values. What was once a minor business expense can now hit six figures with a single burst pipe or ice dam incident. Meanwhile, insurance premiums have surged 20.4% on average, leaving property…

Read More
From Zero to 460% Engagement: 6 UGC Campaigns That Broke All the Rules
August 1, 2025

Picture this: You spend months crafting the perfect marketing campaign. Professional photographers, expensive equipment, polished copy. You launch it and… crickets. Meanwhile, your competitor posts a simple challenge asking customers to share their stories, and suddenly they’re swimming in engagement, leads, and brand loyalty. Sound familiar? You’re not alone. The biggest mistake brands make with…

Read More
Purpose Factory Event 2025
Lights, Camera, Action
August 1, 2025

The Purpose Factory Event 2025 emerges at a moment when organizations are being challenged to redefine what success really means. Beyond profits and projections, the gathering champions a model of growth that intertwines cultural impact with strategic vision. It’s a forum where companies explore how values can be engineered into operations, not just marketed in…

Read More